Capital RequirementsThe private placement extends cash runway into 2028, providing necessary capital to initiate Phase 2b SAFEGUARD trial.
Market CompetitionSAB-142 has a potential competitive dosing regimen with 2-3 days dosing versus 12-14 days with teplizumab.
Safety ConcernsSAB announced that SAB-142 showed no RBC depletion, no neutropenia, and no thrombocytopenia, which are often concerns with similar treatments.